BRPI0813999A2 - ciclopentanos de pirimidil como inibidores de akt proteína cinase - Google Patents
ciclopentanos de pirimidil como inibidores de akt proteína cinase Download PDFInfo
- Publication number
- BRPI0813999A2 BRPI0813999A2 BRPI0813999A BRPI0813999A BRPI0813999A2 BR PI0813999 A2 BRPI0813999 A2 BR PI0813999A2 BR PI0813999 A BRPI0813999 A BR PI0813999A BR PI0813999 A BRPI0813999 A BR PI0813999A BR PI0813999 A2 BRPI0813999 A2 BR PI0813999A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyrimidin
- ethanone
- piperazin
- dihydro
- methyl
- Prior art date
Links
- -1 pyrimidyl cyclopentanes Chemical class 0.000 title claims abstract 68
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title abstract 3
- 239000003909 protein kinase inhibitor Substances 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 5
- 201000011510 cancer Diseases 0.000 claims abstract description 4
- 230000003463 hyperproliferative effect Effects 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract 81
- 150000003839 salts Chemical class 0.000 claims abstract 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 31
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 21
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 9
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 9
- 230000001404 mediated effect Effects 0.000 claims 8
- 125000004429 atom Chemical group 0.000 claims 7
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 5
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- AJAUYRZUZLBSAI-QEMXTEJRSA-N (2s)-1-[4-[(5r,7r)-7-methoxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-pyrrolidin-2-yl]-2-[4-(trifluoromethyl)phenyl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C2=NC=NC3=C2[C@H](C)C[C@H]3OC)C=2C=CC(=CC=2)C(F)(F)F)CCN1 AJAUYRZUZLBSAI-QEMXTEJRSA-N 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 claims 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 2
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 208000031481 Pathologic Constriction Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 238000010511 deprotection reaction Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 230000036262 stenosis Effects 0.000 claims 2
- 208000037804 stenosis Diseases 0.000 claims 2
- RHFLHCFOTKICHL-YHQLXQCYSA-N (2r)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7s)-7-fluoro-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethanone Chemical compound C([C@H]1[C@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@@H](F)C[C@H](C=23)C)C=2C(=CC(=CC=2)C(F)(F)F)F)CC(C)(C)N1 RHFLHCFOTKICHL-YHQLXQCYSA-N 0.000 claims 1
- GGXGZWAQHASGSZ-JJXUHFIVSA-N (2s)-1-[4-[(5r)-7,7-difluoro-5-methyl-5,6-dihydrocyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3C(F)(F)C[C@H](C=23)C)C=2C(=CC(=CC=2)C(F)(F)F)F)CC(C)(C)N1 GGXGZWAQHASGSZ-JJXUHFIVSA-N 0.000 claims 1
- DASSZTKFRRUZCP-DKOYFPBOSA-N (2s)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-1-methylpyrrolidin-2-yl]-2-(4-methylsulfonylphenyl)ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(=CC=2)S(C)(=O)=O)CCN1C DASSZTKFRRUZCP-DKOYFPBOSA-N 0.000 claims 1
- XFHVYPRSEDNUFU-QEMXTEJRSA-N (2s)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-1-methylpyrrolidin-2-yl]-2-[4-(trifluoromethyl)phenyl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(=CC=2)C(F)(F)F)CCN1C XFHVYPRSEDNUFU-QEMXTEJRSA-N 0.000 claims 1
- FEMSWPPUYTTWKZ-LKRGOLFISA-N (2s)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-pyrrolidin-2-yl]-2-[4-(trifluoromethyl)phenyl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(=CC=2)C(F)(F)F)CCN1 FEMSWPPUYTTWKZ-LKRGOLFISA-N 0.000 claims 1
- RNDKLFPVTJZXMV-DKOYFPBOSA-N (2s)-1-[4-[(5r,7r)-7-methoxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-1-methylpyrrolidin-2-yl]-2-[4-(trifluoromethyl)phenyl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C2=NC=NC3=C2[C@H](C)C[C@H]3OC)C=2C=CC(=CC=2)C(F)(F)F)CCN1C RNDKLFPVTJZXMV-DKOYFPBOSA-N 0.000 claims 1
- GEERFIKIHAKETR-BTIFBSDPSA-N (2s)-2-(3,4-difluorophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=C(F)C(F)=CC=2)CC(C)(C)N1 GEERFIKIHAKETR-BTIFBSDPSA-N 0.000 claims 1
- NSQJPOIAYSLFDI-FHZYATBESA-N (2s)-2-(3-bromophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r)-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3CC[C@H](C=23)C)C=2C=C(Br)C=CC=2)CC(C)(C)N1 NSQJPOIAYSLFDI-FHZYATBESA-N 0.000 claims 1
- SIITXINKIRZLQU-QEMXTEJRSA-N (2s)-2-(3-bromophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=C(Br)C=CC=2)CC(C)(C)N1 SIITXINKIRZLQU-QEMXTEJRSA-N 0.000 claims 1
- BGOWNUNGLJHGKO-FHZYATBESA-N (2s)-2-(3-chlorophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r)-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3CC[C@H](C=23)C)C=2C=C(Cl)C=CC=2)CC(C)(C)N1 BGOWNUNGLJHGKO-FHZYATBESA-N 0.000 claims 1
- PKFWHNKIXDWAHF-QEMXTEJRSA-N (2s)-2-(3-chlorophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=C(Cl)C=CC=2)CC(C)(C)N1 PKFWHNKIXDWAHF-QEMXTEJRSA-N 0.000 claims 1
- YHTSWIVQYCSQER-BTIFBSDPSA-N (2s)-2-(4-bromo-2-fluorophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C(=CC(Br)=CC=2)F)CC(C)(C)N1 YHTSWIVQYCSQER-BTIFBSDPSA-N 0.000 claims 1
- DMMDFDUBQHEPDQ-BTIFBSDPSA-N (2s)-2-(4-bromo-3-fluorophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=C(F)C(Br)=CC=2)CC(C)(C)N1 DMMDFDUBQHEPDQ-BTIFBSDPSA-N 0.000 claims 1
- ZGVMQUGMOPZOJC-PBEJRMEISA-N (2s)-2-(4-bromophenyl)-1-[4-[(5r)-7,7-difluoro-5-methyl-5,6-dihydrocyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3C(F)(F)C[C@H](C=23)C)C=2C=CC(Br)=CC=2)CC(C)(C)N1 ZGVMQUGMOPZOJC-PBEJRMEISA-N 0.000 claims 1
- KOQKCNFHTUUWJI-DEZRYOJYSA-N (2s)-2-(4-bromophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-fluoro-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](F)C[C@H](C=23)C)C=2C=CC(Br)=CC=2)CC(C)(C)N1 KOQKCNFHTUUWJI-DEZRYOJYSA-N 0.000 claims 1
- MCDVPXUUDXCZPQ-QEMXTEJRSA-N (2s)-2-(4-bromophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(Br)=CC=2)CC(C)(C)N1 MCDVPXUUDXCZPQ-QEMXTEJRSA-N 0.000 claims 1
- MCDVPXUUDXCZPQ-SYNNKVJXSA-N (2s)-2-(4-bromophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7s)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@@H](O)C[C@H](C=23)C)C=2C=CC(Br)=CC=2)CC(C)(C)N1 MCDVPXUUDXCZPQ-SYNNKVJXSA-N 0.000 claims 1
- GGAYRRSQBOODLT-LDQFHDLZSA-N (2s)-2-(4-chloro-2,5-difluorophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C(=CC(Cl)=C(F)C=2)F)CC(C)(C)N1 GGAYRRSQBOODLT-LDQFHDLZSA-N 0.000 claims 1
- OCYQNUNFTYVQRE-SURYNDKFSA-N (2s)-2-(4-chloro-2-fluorophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5,7-dimethyl-5,6-dihydrocyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@](C)(O)C[C@H](C=23)C)C=2C(=CC(Cl)=CC=2)F)CC(C)(C)N1 OCYQNUNFTYVQRE-SURYNDKFSA-N 0.000 claims 1
- ZBUKELXFBDMFKY-BTIFBSDPSA-N (2s)-2-(4-chloro-2-fluorophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C(=CC(Cl)=CC=2)F)CC(C)(C)N1 ZBUKELXFBDMFKY-BTIFBSDPSA-N 0.000 claims 1
- AANZSBNNRYHRRN-BZDYGPBWSA-N (2s)-2-(4-chloro-2-fluorophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7s)-7-fluoro-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@@H](F)C[C@H](C=23)C)C=2C(=CC(Cl)=CC=2)F)CC(C)(C)N1 AANZSBNNRYHRRN-BZDYGPBWSA-N 0.000 claims 1
- YEKYBFOXPKLPFD-SURYNDKFSA-N (2s)-2-(4-chloro-3-fluorophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5,7-dimethyl-5,6-dihydrocyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@](C)(O)C[C@H](C=23)C)C=2C=C(F)C(Cl)=CC=2)CC(C)(C)N1 YEKYBFOXPKLPFD-SURYNDKFSA-N 0.000 claims 1
- DBNPCFRCZQQNNM-BZDYGPBWSA-N (2s)-2-(4-chloro-3-fluorophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7s)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@@H](O)C[C@H](C=23)C)C=2C=C(F)C(Cl)=CC=2)CC(C)(C)N1 DBNPCFRCZQQNNM-BZDYGPBWSA-N 0.000 claims 1
- OZZBPRLCCCVZBE-ZNPMGDIFSA-N (2s)-2-(4-chlorophenyl)-1-[(3s)-4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]-3-methylpiperazin-1-yl]-2-[(2s)-pyrrolidin-2-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN([C@H](C2)C)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CCN1 OZZBPRLCCCVZBE-ZNPMGDIFSA-N 0.000 claims 1
- KNIAUQMPYFBCJK-PBEJRMEISA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r)-7,7-difluoro-5-methyl-5,6-dihydrocyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3C(F)(F)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CC(C)(C)N1 KNIAUQMPYFBCJK-PBEJRMEISA-N 0.000 claims 1
- ZVYGXDZKUJTOIX-ZXFPDNNPSA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-fluoro-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-pyrrolidin-2-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](F)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CCN1 ZVYGXDZKUJTOIX-ZXFPDNNPSA-N 0.000 claims 1
- PZDFWZSALKFSMT-ZEFBCVDJSA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2r)-1-methylpyrrolidin-2-yl]ethanone Chemical compound C([C@@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CCN1C PZDFWZSALKFSMT-ZEFBCVDJSA-N 0.000 claims 1
- NEEIYKGPXDSGBL-FEGHXTNJSA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2r)-pyrrolidin-2-yl]ethanone Chemical compound C([C@@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CCN1 NEEIYKGPXDSGBL-FEGHXTNJSA-N 0.000 claims 1
- GNMUHTCTEVMICV-DKOYFPBOSA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-1,5,5-trimethylpyrrolidin-2-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CC(C)(C)N1C GNMUHTCTEVMICV-DKOYFPBOSA-N 0.000 claims 1
- ZOAWIPAEUPZJIV-QBTGUUFSSA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-1-(2-hydroxy-2-methylpropyl)pyrrolidin-2-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CCN1CC(C)(C)O ZOAWIPAEUPZJIV-QBTGUUFSSA-N 0.000 claims 1
- PCTZNUMCLFOXCU-SRPRTCBCSA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-1-(2-methoxyethyl)-5,5-dimethylpyrrolidin-2-yl]ethanone Chemical compound C1CC(C)(C)N(CCOC)[C@@H]1[C@H](C=1C=CC(Cl)=CC=1)C(=O)N1CCN(C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CC1 PCTZNUMCLFOXCU-SRPRTCBCSA-N 0.000 claims 1
- SYVAKCTZZGZWME-QBTGUUFSSA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-1-(2-methoxyethyl)pyrrolidin-2-yl]ethanone Chemical compound COCCN1CCC[C@H]1[C@H](C=1C=CC(Cl)=CC=1)C(=O)N1CCN(C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CC1 SYVAKCTZZGZWME-QBTGUUFSSA-N 0.000 claims 1
- WZMPDSCDRPTBPT-SRPRTCBCSA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-1-(2-methylpropyl)pyrrolidin-2-yl]ethanone Chemical compound CC(C)CN1CCC[C@H]1[C@H](C=1C=CC(Cl)=CC=1)C(=O)N1CCN(C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CC1 WZMPDSCDRPTBPT-SRPRTCBCSA-N 0.000 claims 1
- GGDGKPLGOYLEOE-QBTGUUFSSA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-1-(3-hydroxypropyl)pyrrolidin-2-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CCN1CCCO GGDGKPLGOYLEOE-QBTGUUFSSA-N 0.000 claims 1
- XCXDOUGVTGFDMW-XVZHEKKHSA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-1-(oxan-4-yl)pyrrolidin-2-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CCN1C1CCOCC1 XCXDOUGVTGFDMW-XVZHEKKHSA-N 0.000 claims 1
- YHSDAHWHJFHOGJ-DKOYFPBOSA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-1-methylpiperidin-2-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CCCN1C YHSDAHWHJFHOGJ-DKOYFPBOSA-N 0.000 claims 1
- BLBOCVKCGYAKDP-QBTGUUFSSA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-1-propan-2-ylpyrrolidin-2-yl]ethanone Chemical compound CC(C)N1CCC[C@H]1[C@H](C=1C=CC(Cl)=CC=1)C(=O)N1CCN(C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CC1 BLBOCVKCGYAKDP-QBTGUUFSSA-N 0.000 claims 1
- XLELDVURKKAFNR-QEMXTEJRSA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-piperidin-2-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CCCN1 XLELDVURKKAFNR-QEMXTEJRSA-N 0.000 claims 1
- NEEIYKGPXDSGBL-LKRGOLFISA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-pyrrolidin-2-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CCN1 NEEIYKGPXDSGBL-LKRGOLFISA-N 0.000 claims 1
- QLPNCJOLECYJKL-QEMXTEJRSA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(3r)-4-methylmorpholin-3-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)OCCN1C QLPNCJOLECYJKL-QEMXTEJRSA-N 0.000 claims 1
- PTVFSXRIKOGGFI-LKRGOLFISA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(3r)-morpholin-3-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)OCCN1 PTVFSXRIKOGGFI-LKRGOLFISA-N 0.000 claims 1
- ZVYGXDZKUJTOIX-CCMRYFRJSA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7s)-7-fluoro-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-pyrrolidin-2-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@@H](F)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CCN1 ZVYGXDZKUJTOIX-CCMRYFRJSA-N 0.000 claims 1
- PZDFWZSALKFSMT-SYNNKVJXSA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7s)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-1-methylpyrrolidin-2-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CCN1C PZDFWZSALKFSMT-SYNNKVJXSA-N 0.000 claims 1
- NEEIYKGPXDSGBL-CCMRYFRJSA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7s)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-pyrrolidin-2-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CCN1 NEEIYKGPXDSGBL-CCMRYFRJSA-N 0.000 claims 1
- QLPNCJOLECYJKL-SYNNKVJXSA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7s)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(3r)-4-methylmorpholin-3-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)OCCN1C QLPNCJOLECYJKL-SYNNKVJXSA-N 0.000 claims 1
- PTVFSXRIKOGGFI-CCMRYFRJSA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7s)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(3r)-morpholin-3-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)OCCN1 PTVFSXRIKOGGFI-CCMRYFRJSA-N 0.000 claims 1
- AMNJOBCQNPPENC-WOSKWAQLSA-N (2s)-2-(4-chlorophenyl)-2-[(2s)-1-(2,2-difluoroethyl)pyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CCN1CC(F)F AMNJOBCQNPPENC-WOSKWAQLSA-N 0.000 claims 1
- DOYYJLRNVHHMGU-DKOYFPBOSA-N (2s)-2-(4-chlorophenyl)-2-[(2s)-1-(2-fluoroethyl)pyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CCN1CCF DOYYJLRNVHHMGU-DKOYFPBOSA-N 0.000 claims 1
- DTWAQJRESWWCQZ-DKOYFPBOSA-N (2s)-2-(4-chlorophenyl)-2-[(2s)-1-(2-hydroxyethyl)pyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CCN1CCO DTWAQJRESWWCQZ-DKOYFPBOSA-N 0.000 claims 1
- OJKNLOFSNGKISA-QBTGUUFSSA-N (2s)-2-(4-chlorophenyl)-2-[(2s)-1-ethyl-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C1CC(C)(C)N(CC)[C@@H]1[C@H](C=1C=CC(Cl)=CC=1)C(=O)N1CCN(C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CC1 OJKNLOFSNGKISA-QBTGUUFSSA-N 0.000 claims 1
- OJKNLOFSNGKISA-VPJOFFEXSA-N (2s)-2-(4-chlorophenyl)-2-[(2s)-1-ethyl-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7s)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C1CC(C)(C)N(CC)[C@@H]1[C@H](C=1C=CC(Cl)=CC=1)C(=O)N1CCN(C=2C=3[C@H](C)C[C@H](O)C=3N=CN=2)CC1 OJKNLOFSNGKISA-VPJOFFEXSA-N 0.000 claims 1
- SGYPPIWCNUQKNU-QBTGUUFSSA-N (2s)-2-(4-chlorophenyl)-2-[(2s)-5,5-diethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound N1C(CC)(CC)CC[C@H]1[C@H](C=1C=CC(Cl)=CC=1)C(=O)N1CCN(C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CC1 SGYPPIWCNUQKNU-QBTGUUFSSA-N 0.000 claims 1
- AATFGCSBGPLZTP-WJMWBRGCSA-N (2s)-2-(4-chlorophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-5-(fluoromethyl)-7-hydroxy-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound N1C(C)(C)CC[C@H]1[C@H](C=1C=CC(Cl)=CC=1)C(=O)N1CCN(C=2C=3[C@H](CF)C[C@@H](O)C=3N=CN=2)CC1 AATFGCSBGPLZTP-WJMWBRGCSA-N 0.000 claims 1
- ASVATSKHMUOZCG-WCSGGZKSSA-N (2s)-2-(4-chlorophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5,7-dimethyl-5,6-dihydrocyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@](C)(O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CC(C)(C)N1 ASVATSKHMUOZCG-WCSGGZKSSA-N 0.000 claims 1
- JFTIFYNZZKGWRZ-WJMWBRGCSA-N (2s)-2-(4-chlorophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-(hydroxymethyl)-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound N1C(C)(C)CC[C@H]1[C@H](C=1C=CC(Cl)=CC=1)C(=O)N1CCN(C=2C=3[C@H](CO)C[C@@H](O)C=3N=CN=2)CC1 JFTIFYNZZKGWRZ-WJMWBRGCSA-N 0.000 claims 1
- KOHGXVITISGBPV-QEMXTEJRSA-N (2s)-2-(4-chlorophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CC(C)(C)N1 KOHGXVITISGBPV-QEMXTEJRSA-N 0.000 claims 1
- AXICWQITLRXKEH-DKOYFPBOSA-N (2s)-2-(4-chlorophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-methoxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C2=NC=NC3=C2[C@H](C)C[C@H]3OC)C=2C=CC(Cl)=CC=2)CC(C)(C)N1 AXICWQITLRXKEH-DKOYFPBOSA-N 0.000 claims 1
- KOHGXVITISGBPV-SYNNKVJXSA-N (2s)-2-(4-chlorophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7s)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CC(C)(C)N1 KOHGXVITISGBPV-SYNNKVJXSA-N 0.000 claims 1
- LWAIVXYLRFXPLQ-ZJNJKDKRSA-N (2s)-2-(4-cyclopropylphenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-1-methylpyrrolidin-2-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(=CC=2)C2CC2)CCN1C LWAIVXYLRFXPLQ-ZJNJKDKRSA-N 0.000 claims 1
- GMSADNDLRCPPJI-TVZVLCPFSA-N (2s)-2-(4-cyclopropylphenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-1-propan-2-ylpyrrolidin-2-yl]ethanone Chemical compound CC(C)N1CCC[C@H]1[C@H](C=1C=CC(=CC=1)C1CC1)C(=O)N1CCN(C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CC1 GMSADNDLRCPPJI-TVZVLCPFSA-N 0.000 claims 1
- DNNUTZJOWDKFAP-TYVKFHQSSA-N (2s)-2-(4-cyclopropylphenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[(2s)-pyrrolidin-2-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(=CC=2)C2CC2)CCN1 DNNUTZJOWDKFAP-TYVKFHQSSA-N 0.000 claims 1
- BJLNTTHYSROJML-XVZHEKKHSA-N (2s)-2-(4-cyclopropylphenyl)-2-[(2s)-1-ethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound CCN1CCC[C@H]1[C@H](C=1C=CC(=CC=1)C1CC1)C(=O)N1CCN(C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CC1 BJLNTTHYSROJML-XVZHEKKHSA-N 0.000 claims 1
- JUPHFKZPZRICTE-ZJNJKDKRSA-N (2s)-2-(4-cyclopropylphenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(=CC=2)C2CC2)CC(C)(C)N1 JUPHFKZPZRICTE-ZJNJKDKRSA-N 0.000 claims 1
- JUPHFKZPZRICTE-SPTRTZJMSA-N (2s)-2-(4-cyclopropylphenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7s)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@@H](O)C[C@H](C=23)C)C=2C=CC(=CC=2)C2CC2)CC(C)(C)N1 JUPHFKZPZRICTE-SPTRTZJMSA-N 0.000 claims 1
- POXBGKDKQNKAPI-SRPRTCBCSA-N (2s)-2-(4-tert-butylphenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(=CC=2)C(C)(C)C)CC(C)(C)N1 POXBGKDKQNKAPI-SRPRTCBCSA-N 0.000 claims 1
- WHMFGSWUZHPYBQ-UIVXKWKOSA-N (2s)-2-(5-bromothiophen-2-yl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2SC(Br)=CC=2)CC(C)(C)N1 WHMFGSWUZHPYBQ-UIVXKWKOSA-N 0.000 claims 1
- CJPXKLBOSQMEBL-UIVXKWKOSA-N (2s)-2-(5-chlorothiophen-2-yl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2SC(Cl)=CC=2)CC(C)(C)N1 CJPXKLBOSQMEBL-UIVXKWKOSA-N 0.000 claims 1
- LVLHDTXRNMGABW-QBTGUUFSSA-N (2s)-2-[(2s)-1-azaspiro[4.4]nonan-2-yl]-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H](N1)[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CC21CCCC2 LVLHDTXRNMGABW-QBTGUUFSSA-N 0.000 claims 1
- YYOOIOTXVIMDGC-WCSGGZKSSA-N (2s)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5,7-dimethyl-5,6-dihydrocyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[4-(trifluoromethyl)phenyl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@](C)(O)C[C@H](C=23)C)C=2C=CC(=CC=2)C(F)(F)F)CC(C)(C)N1 YYOOIOTXVIMDGC-WCSGGZKSSA-N 0.000 claims 1
- NUIXBYMQZMFGFF-TYVKFHQSSA-N (2s)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-(1h-indol-3-yl)ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C3=CC=CC=C3NC=2)CC(C)(C)N1 NUIXBYMQZMFGFF-TYVKFHQSSA-N 0.000 claims 1
- FAMGBAKCSHPHBO-DQFIBICCSA-N (2s)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-(4-phenylphenyl)ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(=CC=2)C=2C=CC=CC=2)CC(C)(C)N1 FAMGBAKCSHPHBO-DQFIBICCSA-N 0.000 claims 1
- KNHPRTNPYBKUFV-ZJNJKDKRSA-N (2s)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-[4-(1h-pyrazol-4-yl)phenyl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(=CC=2)C2=CNN=C2)CC(C)(C)N1 KNHPRTNPYBKUFV-ZJNJKDKRSA-N 0.000 claims 1
- DXJUDXWHQMNCRK-QSABTFIQSA-N (2s)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-2-(2-fluoro-4-methoxyphenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound FC1=CC(OC)=CC=C1[C@H](C(=O)N1CCN(CC1)C=1C=2[C@H](C)C[C@@H](O)C=2N=CN=1)[C@H]1NC(C)(C)CC1 DXJUDXWHQMNCRK-QSABTFIQSA-N 0.000 claims 1
- XXFHIVFUODKEQT-QEMXTEJRSA-N (2s)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-2-(3-fluorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=C(F)C=CC=2)CC(C)(C)N1 XXFHIVFUODKEQT-QEMXTEJRSA-N 0.000 claims 1
- NJOPSAGOQVPIBH-QEMXTEJRSA-N (2s)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-2-(4-fluorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(F)=CC=2)CC(C)(C)N1 NJOPSAGOQVPIBH-QEMXTEJRSA-N 0.000 claims 1
- GTFHQLRIFMRUIV-LKRGOLFISA-N (2s)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-2-[2-fluoro-3-(trifluoromethyl)phenyl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C(=C(C=CC=2)C(F)(F)F)F)CC(C)(C)N1 GTFHQLRIFMRUIV-LKRGOLFISA-N 0.000 claims 1
- MARWZZULKRRMKU-BTIFBSDPSA-N (2s)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-2-[2-fluoro-4-(trifluoromethyl)phenyl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C(=CC(=CC=2)C(F)(F)F)F)CC(C)(C)N1 MARWZZULKRRMKU-BTIFBSDPSA-N 0.000 claims 1
- MARWZZULKRRMKU-BZDYGPBWSA-N (2s)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-2-[2-fluoro-4-(trifluoromethyl)phenyl]-1-[4-[(5r,7s)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@@H](O)C[C@H](C=23)C)C=2C(=CC(=CC=2)C(F)(F)F)F)CC(C)(C)N1 MARWZZULKRRMKU-BZDYGPBWSA-N 0.000 claims 1
- LPGFGNDYFYBMRK-BTIFBSDPSA-N (2s)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-2-[2-fluoro-5-(trifluoromethyl)phenyl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C(=CC=C(C=2)C(F)(F)F)F)CC(C)(C)N1 LPGFGNDYFYBMRK-BTIFBSDPSA-N 0.000 claims 1
- AYQHZUUHZNXEBP-LRYKZCBQSA-N (2s)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-2-[3-fluoro-4-(trifluoromethoxy)phenyl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=C(F)C(OC(F)(F)F)=CC=2)CC(C)(C)N1 AYQHZUUHZNXEBP-LRYKZCBQSA-N 0.000 claims 1
- IWLHRLWHFQAHEH-SURYNDKFSA-N (2s)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-2-[3-fluoro-4-(trifluoromethyl)phenyl]-1-[4-[(5r,7r)-7-hydroxy-5,7-dimethyl-5,6-dihydrocyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@](C)(O)C[C@H](C=23)C)C=2C=C(F)C(=CC=2)C(F)(F)F)CC(C)(C)N1 IWLHRLWHFQAHEH-SURYNDKFSA-N 0.000 claims 1
- VERHIYABCPTLIA-BTIFBSDPSA-N (2s)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-2-[3-fluoro-4-(trifluoromethyl)phenyl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=C(F)C(=CC=2)C(F)(F)F)CC(C)(C)N1 VERHIYABCPTLIA-BTIFBSDPSA-N 0.000 claims 1
- VERHIYABCPTLIA-BZDYGPBWSA-N (2s)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-2-[3-fluoro-4-(trifluoromethyl)phenyl]-1-[4-[(5r,7s)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@@H](O)C[C@H](C=23)C)C=2C=C(F)C(=CC=2)C(F)(F)F)CC(C)(C)N1 VERHIYABCPTLIA-BZDYGPBWSA-N 0.000 claims 1
- CXJMFTBYDXROHU-BTIFBSDPSA-N (2s)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-2-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=C(C(F)=CC=2)C(F)(F)F)CC(C)(C)N1 CXJMFTBYDXROHU-BTIFBSDPSA-N 0.000 claims 1
- QGHFVNNDJJNFFE-ZJNJKDKRSA-N (2s)-2-[4-(2-aminopyrimidin-5-yl)phenyl]-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(=CC=2)C=2C=NC(N)=NC=2)CC(C)(C)N1 QGHFVNNDJJNFFE-ZJNJKDKRSA-N 0.000 claims 1
- XPZFCRJDOIPXHQ-WVBUVRCRSA-N (5r)-4-[4-[(2s)-2-(4-chlorophenyl)-2-[(2s)-5,5-dimethylpyrrolidin-2-yl]acetyl]piperazin-1-yl]-5-methyl-5,6-dihydrocyclopenta[d]pyrimidin-7-one Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3C(=O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CC(C)(C)N1 XPZFCRJDOIPXHQ-WVBUVRCRSA-N 0.000 claims 1
- UYSANVPQADKUEN-UTQVJTIVSA-N (5r)-5-[(1s)-1-(4-chlorophenyl)-2-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-oxoethyl]pyrrolidin-2-one Chemical compound C([C@@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CC(=O)N1 UYSANVPQADKUEN-UTQVJTIVSA-N 0.000 claims 1
- DVIKZCZCIOJAFS-UTQVJTIVSA-N (5r)-5-[(1s)-2-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-oxo-1-[4-(trifluoromethyl)phenyl]ethyl]pyrrolidin-2-one Chemical compound C([C@@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(=CC=2)C(F)(F)F)CC(=O)N1 DVIKZCZCIOJAFS-UTQVJTIVSA-N 0.000 claims 1
- UYSANVPQADKUEN-IZQPOCBFSA-N (5s)-5-[(1s)-1-(4-chlorophenyl)-2-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-oxoethyl]pyrrolidin-2-one Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(Cl)=CC=2)CC(=O)N1 UYSANVPQADKUEN-IZQPOCBFSA-N 0.000 claims 1
- DVIKZCZCIOJAFS-IZQPOCBFSA-N (5s)-5-[(1s)-2-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-oxo-1-[4-(trifluoromethyl)phenyl]ethyl]pyrrolidin-2-one Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(=CC=2)C(F)(F)F)CC(=O)N1 DVIKZCZCIOJAFS-IZQPOCBFSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- GNFLFJHEDPTEJO-MWLCHTKSSA-N 1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C1([C@H](O)C[C@H](C=21)C)=NC=NC=2N1CCN(C(C)=O)CC1 GNFLFJHEDPTEJO-MWLCHTKSSA-N 0.000 claims 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- QKEYJDGHEWEOME-QSABTFIQSA-N 4-[(1s)-1-[(2s)-5,5-dimethylpyrrolidin-2-yl]-2-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-oxoethyl]-2-fluorobenzonitrile Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=C(F)C(C#N)=CC=2)CC(C)(C)N1 QKEYJDGHEWEOME-QSABTFIQSA-N 0.000 claims 1
- UBLVXRGFUNXRSK-DKOYFPBOSA-N 4-[(1s)-1-[(2s)-5,5-dimethylpyrrolidin-2-yl]-2-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-2-oxoethyl]benzonitrile Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(=CC=2)C#N)CC(C)(C)N1 UBLVXRGFUNXRSK-DKOYFPBOSA-N 0.000 claims 1
- ZZEAOIRAKVHWDF-DKOYFPBOSA-N 4-[(1s)-2-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-1-[(2s)-1-methylpyrrolidin-2-yl]-2-oxoethyl]benzonitrile Chemical compound C([C@H]1[C@@H](C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)C=2C=CC(=CC=2)C#N)CCN1C ZZEAOIRAKVHWDF-DKOYFPBOSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- 208000003120 Angiofibroma Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 201000007815 Bannayan-Riley-Ruvalcaba syndrome Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000012609 Cowden disease Diseases 0.000 claims 1
- 201000002847 Cowden syndrome Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 208000022010 Lhermitte-Duclos disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 229960003685 imatinib mesylate Drugs 0.000 claims 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 claims 1
- MOZRQQTUYAYCQT-FQEVSTJZSA-N n-[[(3s)-3-amino-1-(5-ethyl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrolidin-3-yl]methyl]-2,4-difluorobenzamide Chemical compound C([C@]1(CCN(C1)C=1N=CN=C2NC=C(C=12)CC)N)NC(=O)C1=CC=C(F)C=C1F MOZRQQTUYAYCQT-FQEVSTJZSA-N 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 229940034785 sutent Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 229960001196 thiotepa Drugs 0.000 claims 1
- 230000009772 tissue formation Effects 0.000 claims 1
- 230000017423 tissue regeneration Effects 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- LLDWLPRYLVPDTG-UHFFFAOYSA-N vatalanib succinate Chemical compound OC(=O)CCC(O)=O.C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 LLDWLPRYLVPDTG-UHFFFAOYSA-N 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 description 6
- 108060006633 protein kinase Proteins 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 0 *C(CNCC1)N1c1c(C(*)(*)CC2(*)*)c2ncn1 Chemical compound *C(CNCC1)N1c1c(C(*)(*)CC2(*)*)c2ncn1 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94813807P | 2007-07-05 | 2007-07-05 | |
| US2008808P | 2008-01-09 | 2008-01-09 | |
| PCT/US2008/069144 WO2009006567A2 (en) | 2007-07-05 | 2008-07-03 | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0813999A2 true BRPI0813999A2 (pt) | 2019-10-01 |
Family
ID=40076864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0813999A BRPI0813999A2 (pt) | 2007-07-05 | 2008-07-03 | ciclopentanos de pirimidil como inibidores de akt proteína cinase |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8618097B2 (https=) |
| EP (1) | EP2170863B1 (https=) |
| JP (2) | JP5628028B2 (https=) |
| KR (2) | KR101650956B1 (https=) |
| CN (2) | CN103396409B (https=) |
| AR (1) | AR067413A1 (https=) |
| AU (1) | AU2008272830B8 (https=) |
| BR (1) | BRPI0813999A2 (https=) |
| CA (1) | CA2692502C (https=) |
| CO (1) | CO6251283A2 (https=) |
| CR (1) | CR11229A (https=) |
| EC (1) | ECSP109937A (https=) |
| ES (1) | ES2551352T3 (https=) |
| MA (1) | MA31679B1 (https=) |
| NZ (1) | NZ582692A (https=) |
| RU (1) | RU2486181C2 (https=) |
| SG (1) | SG185274A1 (https=) |
| TW (1) | TWI450720B (https=) |
| WO (1) | WO2009006567A2 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008036540A2 (en) | 2006-09-20 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
| US8841304B2 (en) | 2008-01-08 | 2014-09-23 | Array Biopharma, Inc. | Pyrrolopyridines as kinase inhibitors |
| CA2711782C (en) | 2008-01-09 | 2017-01-03 | Array Biopharma Inc. | 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors |
| CN102015708B (zh) * | 2008-01-09 | 2014-03-26 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
| NZ586346A (en) | 2008-01-09 | 2012-02-24 | Array Biopharma Inc | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| US8853216B2 (en) | 2008-01-09 | 2014-10-07 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor |
| CN101965347B (zh) | 2008-01-09 | 2013-01-02 | 阵列生物制药公司 | 作为激酶抑制剂的吡唑并吡啶 |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| EP3053913B1 (en) | 2009-05-01 | 2018-03-07 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| MX2012011887A (es) | 2010-04-16 | 2012-11-30 | Genentech Inc | Foxo 3a como biomarcador predictivo para la eficacia del inhibidor de la via de quinasa pi3k/akt. |
| EP3617330B1 (en) | 2011-04-01 | 2023-12-27 | Genentech, Inc. | Biomarkers for predicting sensitivity to cancer treatments |
| HRP20200992T1 (hr) | 2012-05-17 | 2020-10-16 | Genentech, Inc. | Amorfni oblik pirimidinil-ciklopentanskog spoja koji inhibira akt, te njegovi pripravci i postupci |
| JP6163205B2 (ja) | 2012-06-20 | 2017-07-12 | ノバルティス アーゲー | 補体経路モジュレーターおよびその使用 |
| CA2901126C (en) | 2013-02-25 | 2022-01-25 | Genentech, Inc. | Methods and compositions for detecting and treating drug resistant akt mutant |
| DK3811943T3 (da) | 2013-03-15 | 2023-04-03 | Aerie Pharmaceuticals Inc | Forbindelse til anvendelse til behandling af øjenlidelser |
| US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| US10550087B2 (en) | 2015-11-17 | 2020-02-04 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| AU2017281907B2 (en) | 2016-06-23 | 2021-10-21 | St. Jude Children's Research Hospital, Inc. | Small molecule modulators of pantothenate kinases |
| KR102568079B1 (ko) | 2016-08-31 | 2023-08-17 | 에어리 파마슈티컬즈, 인코포레이티드 | 안과용 조성물 |
| EP3532464A4 (en) | 2016-10-28 | 2020-07-08 | Icahn School of Medicine at Mount Sinai | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER |
| KR20190135027A (ko) | 2017-03-31 | 2019-12-05 | 에어리 파마슈티컬즈, 인코포레이티드 | 아릴 시클로프로필-아미노-이소퀴놀리닐 아미드 화합물 |
| KR102728619B1 (ko) | 2017-12-27 | 2024-11-08 | 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 | 판토테네이트 키나제의 소분자 조절제 |
| CA3092677A1 (en) * | 2018-03-06 | 2019-09-12 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (akt) degradation / disruption compounds and methods of use |
| KR20210006356A (ko) * | 2018-04-04 | 2021-01-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해 조절제 및 연관된 사용 방법 |
| CA3104298A1 (en) | 2018-06-21 | 2019-12-26 | Icahn School Of Medicine At Mount Sinai | Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use |
| AU2019337703B2 (en) | 2018-09-14 | 2023-02-02 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| CA3135011A1 (en) * | 2019-03-27 | 2020-10-01 | St. Jude Children's Research Hospital | Small molecule modulators of pank |
| CN118908962A (zh) | 2019-05-06 | 2024-11-08 | 西奈山伊坎医学院 | 作为hpk1的降解剂的异双功能化合物 |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| CN117677614A (zh) * | 2021-12-17 | 2024-03-08 | 中国医药研究开发中心有限公司 | 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途 |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3885035A (en) | 1972-04-05 | 1975-05-20 | Sandoz Ag | Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines |
| US3956495A (en) | 1973-10-30 | 1976-05-11 | Eli Lilly And Company | 2,4-Diaminoquinazolines as antithrombotic agents |
| US3966936A (en) | 1974-02-21 | 1976-06-29 | Pfizer Inc. | Piperazino quinazoline bronchodilators |
| US4060615A (en) | 1976-02-18 | 1977-11-29 | Mead Johnson & Company | 2-Piperazinyl-6,7-dimethoxyquinazolines |
| JPS562968A (en) | 1979-06-21 | 1981-01-13 | Mitsubishi Yuka Yakuhin Kk | Novel pyrimidine derivative |
| US4749704A (en) | 1985-03-07 | 1988-06-07 | Sankyo Company Limited | Cyclopenta[d]pyrimidine derivatives and use as antidepressants |
| MX19185A (es) | 1989-01-20 | 1993-12-01 | Pfizer | Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas. |
| WO1994007890A1 (fr) | 1992-10-05 | 1994-04-14 | Ube Industries, Ltd. | Compose pyrimidine |
| WO1995003286A1 (en) | 1993-07-23 | 1995-02-02 | The Green Cross Corporation | Triazole derivative and pharmaceutical use thereof |
| GB9416189D0 (en) | 1994-08-10 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
| JP2896532B2 (ja) | 1994-08-13 | 1999-05-31 | ユーハン コーポレーション | 新規なピリミジン誘導体およびその製造方法 |
| US5525625A (en) | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
| US7125880B1 (en) | 1995-06-06 | 2006-10-24 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| ZA979961B (en) | 1996-11-15 | 1999-05-05 | Lilly Co Eli | 5-HT1F agonists |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| NZ501276A (en) | 1997-07-01 | 2000-10-27 | Warner Lambert Co | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders |
| CA2290509A1 (en) | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
| US6310060B1 (en) | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| US6821963B2 (en) | 1997-07-01 | 2004-11-23 | Warner-Lambert Company | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
| US6506798B1 (en) | 1997-07-01 | 2003-01-14 | Warner-Lambert Company | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors |
| DE69943144D1 (de) | 1998-03-31 | 2011-03-03 | Kyowa Hakko Kirin Co Ltd | Stickstoffenthaltende heterocyclische verbindungen |
| DE19853278A1 (de) | 1998-11-19 | 2000-05-25 | Aventis Pharma Gmbh | Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| AU2203800A (en) | 1999-01-07 | 2000-07-24 | Warner-Lambert Company | Antiviral method using mek inhibitors |
| JP2002534380A (ja) | 1999-01-07 | 2002-10-15 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤による喘息の治療 |
| CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| CA2355470C (en) | 1999-01-13 | 2008-09-30 | Warner-Lambert Company | Benzoheterocycles and their use as mek inhibitors |
| EP1144372B1 (en) | 1999-01-13 | 2005-11-30 | Warner-Lambert Company Llc | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
| CA2349832A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
| HUP0105092A3 (en) | 1999-01-13 | 2003-12-29 | Warner Lambert Co | 1-heterocycle substituted diarylamines and medicaments containing them |
| EP1150950A2 (en) | 1999-01-13 | 2001-11-07 | Warner-Lambert Company | Anthranilic acid derivatives |
| GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| EP1202732A2 (en) | 1999-07-16 | 2002-05-08 | Warner-Lambert Company Llc | Method for treating chronic pain using mek inhibitors |
| CA2377092A1 (en) | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
| JP2003504401A (ja) | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法 |
| JP2003504400A (ja) | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤を用いた慢性痛の治療方法 |
| BR0109188A (pt) | 2000-03-15 | 2003-03-18 | Warner Lambert Co | Diarilaminas 5-amida substituìdas como inibidores de mex |
| DZ3401A1 (fr) | 2000-07-19 | 2002-01-24 | Warner Lambert Co | Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques |
| KR20030059115A (ko) | 2000-08-25 | 2003-07-07 | 워너-램버트 캄파니 엘엘씨 | Ｎ-아릴-안트라닐산 및 그의 유도체의 제조 방법 |
| EP1317450B1 (en) * | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP1337524A1 (en) | 2000-11-02 | 2003-08-27 | AstraZeneca AB | Substituted quinolines as antitumor agents |
| WO2002083139A1 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
| IL158062A0 (en) | 2001-04-30 | 2004-03-28 | Glaxo Group Ltd | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) |
| AU2002336462A1 (en) | 2001-09-06 | 2003-03-24 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| EP1482944A4 (en) | 2002-03-13 | 2006-04-19 | Array Biopharma Inc | NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS |
| CA2481241C (en) | 2002-04-08 | 2010-07-27 | Merck & Co., Inc. | Fused quinoxaline derivatives as inhibitors of akt activity |
| US7223738B2 (en) | 2002-04-08 | 2007-05-29 | Merck & Co., Inc. | Inhibitors of Akt activity |
| EP1494675A4 (en) | 2002-04-08 | 2006-07-19 | Merck & Co Inc | HEMMER OF ACT ACTIVITY |
| CA2480880C (en) | 2002-04-08 | 2011-03-22 | Merck & Co., Inc. | Inhibitors of akt activity |
| JP2005534632A (ja) | 2002-05-10 | 2005-11-17 | ニューロクライン バイオサイエンセズ， インコーポレイテッド | メラノコルチンレセプターリガンドとしての置換ピペラジン |
| US20040102360A1 (en) | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
| JP2006507299A (ja) | 2002-10-30 | 2006-03-02 | メルク エンド カムパニー インコーポレーテッド | Ａｋｔ活性の阻害薬 |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| EP1620095A4 (en) | 2003-04-24 | 2009-04-01 | Merck & Co Inc | HEMMER OF ACT ACTIVITY |
| DE602004022819D1 (de) | 2003-06-06 | 2009-10-08 | Vertex Pharma | Von atp-bindende kassette transportern |
| ZA200601859B (en) | 2003-08-05 | 2008-03-26 | Vertex Pharma | Condensed pyrimidine compounds as inhibitors of voltagegated ion channels |
| JP2007501821A (ja) | 2003-08-12 | 2007-02-01 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｆｒアンタゴニストとしてのテトラヒドロキナゾリン誘導体 |
| MXPA06002618A (es) | 2003-09-09 | 2006-06-05 | Ono Pharmaceutical Co | Antagonistas del factor de liberacion de corticotropina (crf) y compuestos heterobiciclicos. |
| US20050182061A1 (en) | 2003-10-02 | 2005-08-18 | Jeremy Green | Phthalimide compounds useful as protein kinase inhibitors |
| CA2546754A1 (en) * | 2003-11-21 | 2005-06-09 | Array Biopharma Inc. | Akt protein kinase inhibitors |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| WO2005113762A1 (en) | 2004-05-18 | 2005-12-01 | Pfizer Products Inc. | CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF |
| US20060025074A1 (en) | 2004-07-30 | 2006-02-02 | Chih-Ming Liang | Bluetooth-based headset |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| GB0419161D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| TWM266655U (en) | 2004-09-23 | 2005-06-01 | Blueexpert Technology Corp | Bluetooth earphone device capable of wirelessly receiving and transmitting stereo sound signal and digital information signal |
| TW200621257A (en) * | 2004-10-20 | 2006-07-01 | Astellas Pharma Inc | Pyrimidine derivative fused with nonaromatic ring |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| CA2590961C (en) * | 2004-12-28 | 2013-11-26 | Exelixis, Inc. | [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| US20090111805A1 (en) | 2005-02-24 | 2009-04-30 | Pfizer Inc. | Bicyclic heteroaromatic derivatives useful as anticancer agents |
| US20090029982A1 (en) * | 2005-04-28 | 2009-01-29 | Supergen, Inc. | Protein kinase inhibitors |
| WO2006127587A1 (en) | 2005-05-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| US8008317B2 (en) | 2005-06-10 | 2011-08-30 | Merck Sharp & Dohme Corp. | Inhibitors of akt activtiy |
| UY29610A1 (es) | 2005-06-21 | 2007-01-31 | Cancer Rec Tech Ltd | Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica |
| WO2007042298A1 (en) | 2005-10-13 | 2007-04-19 | Glaxo Group Limited | Pyrrolopyrimidine derivatives as syk inhibitors |
| CA2635541A1 (en) | 2005-12-28 | 2007-07-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands |
| JP2009534454A (ja) | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| GB0613518D0 (en) | 2006-07-06 | 2006-08-16 | Phytopharm Plc | Chemical compounds |
| US8063050B2 (en) * | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| US8329701B2 (en) * | 2006-07-06 | 2012-12-11 | Array Biopharma Inc. | Dihydrofuro pyrimidines as AKT protein kinase inhibitors |
| EP2049500B1 (en) | 2006-07-06 | 2011-09-07 | Array Biopharma, Inc. | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| CA2655675A1 (en) | 2006-07-06 | 2008-01-10 | Glaxo Group Limited | Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use |
| UA95641C2 (xx) | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5228912B2 (ja) * | 2006-09-08 | 2013-07-03 | 三菱瓦斯化学株式会社 | 高血圧改善剤 |
| US7741347B2 (en) * | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN101918373B (zh) * | 2007-07-05 | 2013-06-05 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
| US8629171B2 (en) * | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| US8853216B2 (en) * | 2008-01-09 | 2014-10-07 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor |
| CA2711782C (en) * | 2008-01-09 | 2017-01-03 | Array Biopharma Inc. | 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors |
| NZ586346A (en) * | 2008-01-09 | 2012-02-24 | Array Biopharma Inc | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7906655B2 (en) * | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2010096462A1 (en) * | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
| PT3309157T (pt) * | 2009-05-13 | 2019-12-02 | Gilead Pharmasset Llc | Compostos antivirais |
-
2008
- 2008-07-03 CN CN201310128477.3A patent/CN103396409B/zh active Active
- 2008-07-03 CA CA2692502A patent/CA2692502C/en not_active Expired - Fee Related
- 2008-07-03 RU RU2010103813/04A patent/RU2486181C2/ru active
- 2008-07-03 ES ES08781337.4T patent/ES2551352T3/es active Active
- 2008-07-03 BR BRPI0813999A patent/BRPI0813999A2/pt not_active Application Discontinuation
- 2008-07-03 TW TW097125055A patent/TWI450720B/zh not_active IP Right Cessation
- 2008-07-03 JP JP2010515269A patent/JP5628028B2/ja active Active
- 2008-07-03 WO PCT/US2008/069144 patent/WO2009006567A2/en not_active Ceased
- 2008-07-03 KR KR1020107002558A patent/KR101650956B1/ko not_active Expired - Fee Related
- 2008-07-03 US US12/667,848 patent/US8618097B2/en active Active
- 2008-07-03 AU AU2008272830A patent/AU2008272830B8/en not_active Ceased
- 2008-07-03 KR KR1020157020046A patent/KR20150089099A/ko not_active Ceased
- 2008-07-03 SG SG2012073854A patent/SG185274A1/en unknown
- 2008-07-03 AR ARP080102885A patent/AR067413A1/es unknown
- 2008-07-03 NZ NZ582692A patent/NZ582692A/en not_active IP Right Cessation
- 2008-07-03 CN CN2008801058695A patent/CN101801955B/zh active Active
- 2008-07-03 EP EP08781337.4A patent/EP2170863B1/en active Active
-
2010
- 2010-01-19 CR CR11229A patent/CR11229A/es unknown
- 2010-01-29 CO CO10009431A patent/CO6251283A2/es active IP Right Grant
- 2010-02-04 EC EC2010009937A patent/ECSP109937A/es unknown
- 2010-02-05 MA MA32596A patent/MA31679B1/fr unknown
-
2013
- 2013-10-02 JP JP2013207007A patent/JP2014028842A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0813999A2 (pt) | ciclopentanos de pirimidil como inibidores de akt proteína cinase | |
| JP4667463B2 (ja) | チロシンキナーゼ阻害剤として適する環状ジアリールウレア | |
| CN100412066C (zh) | 用作蛋白激酶抑制剂的化合物和组合物 | |
| JP6542212B2 (ja) | ブロモドメイン阻害剤としての新規キナゾリノン | |
| JP5235887B2 (ja) | Ｒｈｏキナーゼ阻害剤 | |
| KR20220090431A (ko) | Sos1 억제제로서의 신규한 퀴나졸린 유도체 화합물 및 이의 용도 | |
| DK2643313T3 (en) | Quinazolincarboxamidazetidiner | |
| CN105481862B (zh) | Flt3激酶的新型抑制剂及其用途 | |
| NZ790920A (en) | Heteroaryl derivative, method for producing the same, and pharmaceutical composition comprising same as effective component | |
| JP2012136537A (ja) | キナゾリン化合物 | |
| HRP20040267A2 (en) | Chemical compounds | |
| CA2697077A1 (en) | 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors | |
| NZ525892A (en) | Phenylacetamido- pyrazole derivatives their use as antitumor agents and preparation process thereof | |
| WO2017049462A1 (zh) | 一类新型的flt3激酶抑制剂及其用途 | |
| TW201629041A (zh) | 新穎化合物及其用於治療發炎病症及骨關節炎之醫藥組合物 | |
| JP2008535780A (ja) | 化合物 | |
| KR20140117684A (ko) | 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물 | |
| CN101796046A (zh) | 嘧啶衍生物934 | |
| KR20130102060A (ko) | 퀴나졸린 화합물 및 이의 사용 방법 | |
| JP2025522388A (ja) | Ｋｒａｓ阻害剤としてのテトラヒドロピリド３，４－ｄピリミジン誘導体 | |
| AU2017342928A1 (en) | Quinoxaline compounds as type III receptor tyrosine kinase inhibitors | |
| CN108368060B (zh) | 一类嘧啶类衍生物激酶抑制剂 | |
| WO2016065461A1 (en) | Ripk2 inhibitors and method of treating cancer with same | |
| CN102770182B (zh) | 被取代的异喹啉酮类和喹唑酮类 | |
| WO2017206962A1 (zh) | Flt3激酶的新型抑制剂及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |